Ablynx
Euronext: ABLX[1]
IndustryBiotechnology
Founded2001 Edit this on Wikidata
Headquarters,
Belgium Edit this on Wikidata
Number of employees
450
Websitewww.ablynx.com

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.[3] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[4]

In January 2018, they were acquired by Sanofi for $4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.[5]

References

  1. "Share Information". Ablynx. Exchange Information. Archived from the original on 2018-05-15. Retrieved 2018-05-14.
  2. "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012. Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.
  3. "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018.
  4. "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018.
  5. "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.

Further reading

  • Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
  • De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.